Paper20121758
IPF: new insight on pathogenesis and treatment.
Harari S and 1 other. Allergy, 2010. Cited by 96 papers, by iCite.
Cite this record
ConductScience Library. IPF: new insight on pathogenesis and treatment. Papers, record 20121758. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20121758
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics3
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Idiopathic Pulmonary Fibrosis | Major topic |
| Animals | |
| Humans |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT05828953 | Anlotinib Capsules in the Treatment for IPF/PF-ILDs | Background |
Source ClinicalTrials.gov
Cited by50
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 96 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42400038 | Identification and functional validation of lactylation-related hub genes in idiopathic pulmonary fibrosis based on multi-omics analysis. | Respir Res | 2026 | https://conductscience.org/library/papers/42400038 | PubMed |
| 40848531 | miR-146b disrupts the epidermal growth factor receptor/transforming growth factor β receptor profibrotic feedforward loop to inhibit lung fibroblast proliferation and differentiation. | J Pharmacol Exp Ther | 2025 | https://conductscience.org/library/papers/40848531 | PubMed |
| 40183147 | Role of Essential Oils and Antioxidants in the Treatment of Fibrosis. | Curr Drug Res Rev | 2025 | https://conductscience.org/library/papers/40183147 | PubMed |
| 39346776 | Role of telomere dysfunction and immune infiltration in idiopathic pulmonary fibrosis: new insights from bioinformatics analysis. | Front Genet | 2024 | https://conductscience.org/library/papers/39346776 | PubMed |
| 39129313 | SPP1 promotes the polarization of M2 macrophages through the Jak2/Stat3 signaling pathway and accelerates the progression of idiopathic pulmonary fibrosis. | Int J Mol Med | 2024 | https://conductscience.org/library/papers/39129313 | PubMed |
| 38791861 | Improving Accessibility to Patients with Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America. | Int J Environ Res Public Health | 2024 | https://conductscience.org/library/papers/38791861 | PubMed |
| 38570751 | Genetic association between smoking and DLCO in idiopathic pulmonary fibrosis patients. | BMC Pulm Med | 2024 | https://conductscience.org/library/papers/38570751 | PubMed |
| 37995089 | Therapeutic potential of melatonin in targeting molecular pathways of organ fibrosis. | Pharmacol Rep | 2024 | https://conductscience.org/library/papers/37995089 | PubMed |
| 37523510 | NFATc3 Promotes Pulmonary Inflammation and Fibrosis by Regulating Production of CCL2 and CXCL2 in Macrophages. | Aging Dis | 2023 | https://conductscience.org/library/papers/37523510 | PubMed |
| 37416778 | FOXO3 regulates Smad3 and Smad7 through SPON1 circular RNA to inhibit idiopathic pulmonary fibrosis. | Int J Biol Sci | 2023 | https://conductscience.org/library/papers/37416778 | PubMed |
| 37254717 | Searching for Novel Candidate Small Molecules for Ameliorating Idiopathic Pulmonary Fibrosis: a Narrative Review. | Biomol Ther (Seoul) | 2023 | https://conductscience.org/library/papers/37254717 | PubMed |
| 36830702 | CC Chemokines in Idiopathic Pulmonary Fibrosis: Pathogenic Role and Therapeutic Potential. | Biomolecules | 2023 | https://conductscience.org/library/papers/36830702 | PubMed |
| 36139759 | The Role of Nrf2 in Pulmonary Fibrosis: Molecular Mechanisms and Treatment Approaches. | Antioxidants (Basel) | 2022 | https://conductscience.org/library/papers/36139759 | PubMed |
| 35059991 | Influence of chest wall conformation on spirometry parameters and outcome in mild-to-moderate idiopathic pulmonary fibrosis. | Intern Emerg Med | 2022 | https://conductscience.org/library/papers/35059991 | PubMed |
| 35003060 | Analyses of circRNA and mRNA Profiles in Vogt-Koyanagi-Harada Disease. | Front Immunol | 2021 | https://conductscience.org/library/papers/35003060 | PubMed |
| 34744424 | Microbiota and IPF: hidden and detected relationships. | Sarcoidosis Vasc Diffuse Lung Dis | 2021 | https://conductscience.org/library/papers/34744424 | PubMed |
| 34275342 | The perplexing role of RAGE in pulmonary fibrosis: causality or casualty? | Ther Adv Respir Dis | 2021 | https://conductscience.org/library/papers/34275342 | PubMed |
| 32899090 | Using bioinformatics approach identifies key genes and pathways in idiopathic pulmonary fibrosis. | Medicine (Baltimore) | 2020 | https://conductscience.org/library/papers/32899090 | PubMed |
| 32712053 | TGF-β1-induced miR-424 promotes pulmonary myofibroblast differentiation by targeting Slit2 protein expression. | Biochem Pharmacol | 2020 | https://conductscience.org/library/papers/32712053 | PubMed |
| 32692932 | Type I Collagen Signaling Regulates Opposing Fibrotic Pathways through α2β1 Integrin. | Am J Respir Cell Mol Biol | 2020 | https://conductscience.org/library/papers/32692932 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20121758
GET https://conductscience.org/api/papers/v1/20121758/cited_by?page=2